Indo US Bio-Tech Ltd
₹104.19
(0.68%)
Mon, 23 Mar 2026, 08:36 am
Process Industries
Agricultural Commodities/Milling
24.5KIndo US Bio-Tech EV/EBITDA Ratio
| Particulars | 2016 | 2017 | 2018 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 23.62 | 7.89 | 28.31 | 54.01 | 18.15 |
| Price to book ratio | 0 | 0 | 3.66 | 1.59 | 3.91 | 7.09 | 3.76 |
| Price to sales ratio | 0 | 0 | 1.40 | 0.83 | 3.32 | 6.11 | 2.84 |
| Price to cash flow ratio | 0 | 0 | 0 | 23.81 | 0 | 615.12 | 378550 |
| Enterprise value | 0 | 0 | 554.14M | 537.61M | 2.16B | 4.58B | 3.1B |
| Enterprise value to EBITDA ratio | 0 | 0 | 16.07 | 7.74 | 23.03 | 41.97 | 16.22 |
| Debt to equity ratio | 1.39 | 1.27 | 0.44 | 0.32 | 0.21 | 0.23 | 0.19 |
| Return on equity % | 0 | 34.36 | 22.16 | 0 | 15.57 | 14.06 | 23.03 |
Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio
The Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Indo US Bio-Tech Ltd's valuation, profitability, and overall financial performance. Tracking the Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Indo US Bio-Tech Ltd (NSE: INDOUS, BSE: 541304) is currently trading at ₹104.19, with a market capitalization of ₹2.11B. As a leading company in the Process industries sector and Agricultural commodities/Milling industry, monitoring the Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.
Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio Current Value
The current Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio stands at 16.22.
The Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio Historical Trend
The Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:
- 2024: 16.22
- 2023: 41.97
- 2022: 23.03
- 2021: 7.74
- 2018: 16.07
The decline in Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio indicates improving financial efficiency or better earnings growth.
What Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio Indicates for Investors
The Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Indo US Bio-Tech Ltd.
Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio Analysis Summary
The Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Indo US Bio-Tech Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800